Home › NDC Lookup › Ingredients › Desonide Ointment, 0.05% › 21922-0004-04
🧴image loading
(from DailyMed)

Desonide Ointment, 0.05% .5 mg/g Ointment — NDC 21922-004-04 (Billing 21922-0004-04)

by Encube Ethicals, Inc. · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of Desonide Ointment, 0.05% .5 mg/g Ointment from Encube Ethicals, Inc., marketed since Mar 2019 and currently FDA-listed; retail pharmacies pay about $0.3921 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 21922-0004-04
🏷️ FDA NDC (as labeled) 21922-004-04 billing pads the product segment with a zero
This package
Contains15 g in 1 tube Cost per g$0.3921 NADAC Per package$5.88 / 15 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.6753/unit · Part D plans $0.6421/unit — full pricing hub ↓
Main listing for product 21922-004 · Also comes in: 60 g 21922-004-07
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 21922-004-04
Product NDC 21922-004
11-digit billing NDC 21922000404
NCPDP billing unit GM — per gram (weight)
RxCUI 204135
UNII J280872D1O
UPC 0321922004076, 0321922004045
Application # ANDA210998
SPL Set ID 3d4d19d4-e47b-407e-9df4-fed5f3db91b9
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-03-20
Route TOPICAL
Dosage form OINTMENT
Substance DESONIDE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90550035004205
GPI class Desonide
GCN Seq No 007622
GCN 31430
HICL code 003322
Ingredient (HICL) Desonide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 84:06.08.00
AHFS class Corticosteroids (Skin, Mucous Membrane)
FDB label name DESONIDE 0.05% OINTMENT
FDB brand name Desonide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007622
  • GCN: 31430
  • GPI-14 (Medi-Span): 90550035004205
  • HICL (First Databank): 003322
  • AHFS class code: 84:06.08.00
  • RxCUI (RxNorm): 204135
Why two NDCs? The FDA registers this code as 21922-004-04 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 21922-0004-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids, moderately potent (group II), Corticosteroids, plain
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name DESONIDE 0.05% OINTMENT Ingredient Desonide
📗 Our plain-language guide HelloPharmacist
  • It calms inflammation and itching from skin conditions that respond to steroids. The gel is specifically for mild to moderate eczema (atopic dermatitis) in people 3 months and olde...
  • Put a thin layer on the affected skin and rub it in gently. How many times a day depends on your product, so follow your label and prescriber. Don’t cover the area with tight wraps...
  • Use it for the shortest time that works. The gel should not go past 4 weeks in a row. The cream and ointment should not go past two weeks unless your doctor says so. Stop once your...
  • Mild burning, rash, itching, dryness or irritation where you apply it. Call your doctor if the skin gets worse, thins, looks infected, or if you notice signs of too much steroid in...
📖 Read our full Desonide guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.392 $5.88 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.6753 $10.13 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.6421 $9.63 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $1.139 $0.377
▼ Down 66% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
21922-0004-04 You're viewing this Main listing 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.3921 / g $5.88 2019-03-20 — Active
21922-0004-07 21922-004-07 1 TUBE in 1 CARTON / 60 g in 1 TUBE $0.2566 / g $15.40 2019-03-20 — Active

Per g, this pack runs about 53% above the cheapest pack (NDC 21922-0004-07, $0.2566 vs $0.3921 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 57% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 15 g in 1 tube.
What NDC number is used to bill for this package of Desonide Ointment, 0.05% .5 mg/g Ointment?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Desonide Ointment, 0.05% .5 mg/gthis 21922-0004-04 Encube 1 tube $0.392 AB Availability likely —
Desonide .5 mg/g 45802-0423-35 Padagis 1 tube $0.392 AB Availability likely —
Desonide .5 mg/g 51672-1281-01 Sun 1 tube $0.392 AB Availability likely —
Desonide .5 mg/g 62332-0485-15 Alembic 1 tube $0.392 AB Availability likely —
Desonide .5 mg/g 72603-0164-01 NORTHSTAR 1 tube $0.392 AB Availability likely —
Desonide .5 mg/g 46708-0485-15 Alembic 1 tube — AB FDA listed —
Desonide Ointment, 0.05% .5 mg/g 63629-8481-01 Bryant 1 tube — AB FDA listed —
Desonide Ointment, 0.05% .5 mg/g 63629-8482-01 Bryant 1 tube — AB FDA listed —
Desonide Ointment, 0.05% .5 mg/g 72162-1272-02 Bryant 1 tube — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Mar 2019
📍
2026
Currently FDA-listed
7 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerEncube Ethicals, Inc.
Application holderENCUBE ETHICALS PVT LTD
FDA applicationANDA210998 (ANDA)
Labeler code21922
First marketedMar 2019
Product typeHuman Prescription Drug
Portfolio77 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 41 words ▾

INDICATIONS AND USAGE Desonide ointment USP, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

⏱️ Dosage and Administration 66 words ▾

DOSAGE AND ADMINISTRATION Desonide ointment, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide ointment, 0.05% should not be used with occlusive dressings.

⛔ Contraindications 22 words ▾

CONTRAINDICATIONS Desonide ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 111 words ▾

ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide ointment, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids.

These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation. To report SUSPECTED ADVERSE REACTIONS , contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🤰 Pregnancy 104 words ▾

PREGNANCY Teratogenic effect Pregnancy Category C – Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with desonide ointment, 0.05%.

It is also not known whether desonide ointment, 0.05% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. There are no adequate and well-controlled studies in pregnant women. Desonide ointment, 0.05% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

🧒 Pediatric Use 131 words ▾

Paediatric Use Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment.

Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

🆘 Overdosage 19 words ▾

OVERDOSAGE Topically applied desonide ointment, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

🧬 Clinical Pharmacology 179 words ▾

CLINICAL PHARMACOLOGY Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called, lipocortins.

It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 . Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier.

Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.

Studies performed with desonide ointment, 0.05% indicate that it is in the low range of potency as compared with other topical corticosteroids.

📦 How Supplied / Storage and Handling 72 words ▾

HOW SUPPLIED Desonide ointment USP, 0.05% is available as follows: 15 g tube (NDC 21922-004-04) 60 g tube (NDC 21922-004-07) STORAGE Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Product of Italy Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C1, Madkaim Industrial Estate, Madkaim, Post Mardol, Ponda, Goa-403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713 USA Rev. 11/25

📋 Description 102 words ▾

DESCRIPTION Desonide ointment USP, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11ß,16α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in desonide ointment USP, 0.05% is C 24 H 32 O 6 .

It has the following structural formula: The molecular weight of desonide is 416.51. It is white to off-white powder. The solubility of desonide in distilled water saturated with the ether is 184 mg/L.

Each gram of desonide ointment USP, 0.05% contains 0.5 milligram of desonide microdispersed in a base of white petrolatum. structure.jpg

💬 Information for Patients 87 words ▾

Information for Patients Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

This medication should not be used for any disorder other than that for which it was prescribed. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician. Patients should report to their physician any signs of local adverse reactions.

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression.

This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than two weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppression. No specific studies relevant to potential HPA suppression have been conducted with desonide ointment, 0.05%.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids.

For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS - Pediatric Use ). If irritation develops, desonide ointment, 0.05% should be discontinued and appropriate therapy instituted.

Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used.

If a favorable response does not occur promptly, use of desonide ointment, 0.05% should be discontinued until the infection has been adequately controlled. Desonide ointment, 0.05% should not be used in the presence of infection at the treatment site, hypersensitivity to corticosteroids, or pre-existing skin atrophy. Desonide ointment, 0.05% should not be used in the eyes.

FOR EXTERNAL USE ONLY. Information for Patients Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only.

Avoid contact with the eyes. This medication should not be used for any disorder other than that for which it was prescribed. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.

Patients should report to their physician any signs of local adverse reactions. Laboratory Tests The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test A.M. plasma cortisol test Urinary free cortisol test Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of desonide ointment, 0.05%. PREGNANCY Teratogenic effect Pregnancy Category C – Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels.

Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproductive studies have not been conducted with desonide ointment, 0.05%. It is also not known whether desonide ointment, 0.05% can cause fetal harm when administered to a pregnant woman or can affect… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 67 words ▾

Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when desonide ointment, 0.05% is administered to a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 25 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic, mutagenic, or fertility impairment potential of desonide ointment, 0.05%.

📄 Package Label / Principal Display Panel 34 words ▾

PRINCIPAL DISPLAY PANEL - 15g Tube Carton Desonide Ointment USP, 0.05% 15 g tube (NDC 21922-004-04) PRINCIPAL DISPLAY PANEL - 60g Tube Carton Desonide Ointment USP, 0.05% 60 g tube (NDC 21922-004-07) crt-15g crt-60g

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
15K
Units reimbursed last 4 qtrs
502.1K
Gross reimbursed last 4 qtrs
$339K
Avg / prescription
$22.53
Avg / unit
$0.6753
Latest quarter Q1 2026
4KRx
Medicaid pays / g
$0.6753
gross reimbursed
vs
NADAC / g
$0.3921
acquisition cost
=
Spread
+$0.2832
+72% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
36% FFS 64% MCO
Fee-for-service · 5,345 Rx Managed care · 9,701 Rx
State Medicaid map
Alaska: 2,115 units · 289 per 100k residents AK Maine: 3,255 units · 233 per 100k residents ME Washington: 26,565 units · 340 per 100k residents WA Idaho: 4,545 units · 231 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 15,960 units · 278 per 100k residents MN Wisconsin: no data reported WI Michigan: 405 units · 4.0 per 100k residents MI New York: 10,725 units · 54.8 per 100k residents NY Vermont: 435 units · 67.2 per 100k residents VT New Hampshire: 2,580 units · 184 per 100k residents NH Oregon: 2,835 units · 67.0 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: 630 units · 68.6 per 100k residents SD Iowa: 315 units · 9.8 per 100k residents IA Illinois: 23,025 units · 183 per 100k residents IL Indiana: 9,420 units · 137 per 100k residents IN Ohio: 54,990 units · 467 per 100k residents OH Pennsylvania: 2,340 units · 18.1 per 100k residents PA New Jersey: 1,290 units · 13.9 per 100k residents NJ Massachusetts: 13,335 units · 190 per 100k residents MA California: 36,135 units · 92.7 per 100k residents CA Utah: 11,355 units · 332 per 100k residents UT Colorado: 41,415 units · 705 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 8,835 units · 195 per 100k residents KY West Virginia: no data reported WV Virginia: 7,290 units · 83.6 per 100k residents VA Maryland: 18,615 units · 301 per 100k residents MD Connecticut: 9,390 units · 260 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: 495 units · 23.4 per 100k residents NM Kansas: 5,790 units · 197 per 100k residents KS Arkansas: no data reported AR Tennessee: 6,720 units · 94.3 per 100k residents TN North Carolina: 41,655 units · 384 per 100k residents NC South Carolina: 24,735 units · 460 per 100k residents SC Delaware: no data reported DE Oklahoma: 525 units · 13.0 per 100k residents OK Louisiana: 2,115 units · 46.2 per 100k residents LA Mississippi: 12,975 units · 441 per 100k residents MS Alabama: 59,715 units · 1,169 per 100k residents AL Georgia: 28,905 units · 262 per 100k residents GA D.C.: 3,045 units · 448 per 100k residents DC Hawaii: 405 units · 28.2 per 100k residents HI Texas: 7,185 units · 23.6 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
4.01,169
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Alabama 1,169 /100k
2 Colorado 705 /100k
3 Ohio 467 /100k
4 South Carolina 460 /100k
5 D.C. 448 /100k
6 Mississippi 441 /100k
7 North Carolina 384 /100k
8 Washington 340 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page21922-0004-04 15,046 Rx · $339,024
1 tube21922-0004-07 11,305 Rx · $353,359
Drug total (last 4 qtrs): 26,351 Rx · 1,189,715 units · $692,384 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
← 21922-0003-01 · Encube 21922-0007-04 · Encube →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.